psoriatic arthritis T-cell Antigen receptor
Conditions
Interventions
This is a comparative study where we investigate the differences in the T-cel receptor profile in PsA patients and psoriasis patients and we study the effects of standard therapy on pathogenic T-cells
From each patient of the PsA group 40ml heparinised peripheral blood, two 4mm biopsies of non-involved buttock skin and 2 biopsies of 4 mm of the involved psoriatic skin, and 20 biopsies of 2 mm of t
Sponsors
Erasmus Medical Centre
Department of Dermatology
Eligibility
Inclusion criteria
Inclusion criteria: PsA group: Adults patients (18-75 years of age, after informed consent), with joint inflammation of one or both knees due to PsA requiring systemic treatment. The patients have failed to respond to, or have a contraindication for cyclosporine and other DMARDS except MTX. Psoriasis group: Adult patients (18-75 years of age, after informed consent) that have psoriasis with a Psoriasis Area and Severity Index (PASI) ¡Ý 10 and/or Body Surface Area (BSA) ¡Ý 10 and/or PASI¡Ý 8 together with skindex ¡Ý 35, that have only psoriasis in their history for at least 10 years, no signs of joint inflammation and that require systemic treatment. The patients have failed to respond to, or have a contraindication for cyclosporine and other DMARDS expect MTX.
Exclusion criteria
Exclusion criteria: 1. Pregnancy and lactation; 2. Active (or chronic) infections including Hepatitis B and C viral infections, HIV and tuberculosis; 3. Malignancy in last 10 years, except BCC and cervical in situ cancer; 4. Treatment of etanercept stopped because of inefficacy, contraindication or serious adverse events, after etanercept therapy for minimal 12 weeks; 5. Demyelinating disease; 6. Congestive heart failure; 7. Allergies and hypersensitivities to potential anti-rheumatic drugs or their ingredients; 8. Any live virus or bacterial vaccination within 3 months; 9. Severe liver function disorders >2 times and/or kidney function disorders >1,5 times upper limits of the reference values.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. The difference(s) in T-cell receptor (TCR-G) profile between psoriatic skin lesions and inflamed knee joint in PsA patients; 2. The difference(s) in T-cell receptor (TCR-G) profile between psoriatic skin lesions in psoriasis patients and psoriatic skin lesions in PsA patients; 3. The difference(s) in T cell gene expression profile from psoriatic skin lesions in psoriasis patients and psoriatic skin lesions of PsA patients; 4. Gene expression profile of T cells from inflamed knee joint of PsA patients. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effects of therapy on pathogenic T cells and their gene expression profile in PsA and psoriasis. | — |
Contacts
Public ContactL.A. Torcque
Department of Dermatology and Venereology Erasmus MC pobox 2040
Outcome results
None listed